Markers of Circulating Breast Cancer Cells

Advances in Clinical Chemistry

Volumn 61, Issue , 2013, Pages 175-224

  López Muñoz, Eunice ^a   Méndez Montes, Manuel ^a  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

Breast cancer; CTC; Metastasis

Indexed keywords

EID: 84878639475     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-407680-8.00007-5     Document Type: Chapter

References (275)

1. Braun S., Pantel K., Müller P., et al. Cytokeratin-positive cells in bone marrow and survival of patients with stage I, II, or III breast cancer. N. Engl. J. Med. 2000, 342:525-533.
2. Bernards R., Weinberg R.A. A progression puzzle. Nature 2002, 418:823.
3. Lin H., Balic M., Zheng S., Datar R., Cote R.J. Disseminated and circulating tumor cells: role in effective cancer management. Crit. Rev. Oncol. Hematol. 2011, 77:1-11.
4. Pantel K., Brakenhoff R.H. Dissecting the metastatic cascade. Nat. Rev. Cancer 2004, 4:448-456.
5. Klein C.A. Parallel progression of primary tumours and metastases. Nat. Rev. Cancer 2009, 9:302-312.
6. Engel J., Eckel R., Kerr J., et al. The process of metastasisation for breast cancer. Eur. J. Cancer 2003, 39:1794-1806.
7. Fehm T., Krawczyk N., Solomayer E.F., et al. ER alpha-status of disseminated tumour cells in bone marrow of primary breast cancer patients. Breast Cancer Res. 2008, 10:R76.
8. Krawczyk N., Banys M., Neubauer H., et al. HER2 status on persistent disseminated tumor cells after adjuvant therapy may differ from initial HER2 status on primary tumor. Anticancer Res. 2009, 29:4019-4024.
9. Banys M., Gruber I., Krawczyk N., et al. Hematogenous and lymphatic tumor cell dissemination may be detected in patients diagnosed with ductal carcinoma in situ of the breast. Breast Cancer Res. Treat. 2012, 131:801-808.
10. Fidler I.J. The pathogenesis of cancer metastasis: the "seed and soil" hypothesis revisited. Nat. Rev. Cancer 2003, 3:453-458.
11. Comen E., Norton L. Self-seeding in cancer. Recent Results Cancer Res. 2012, 195:13-23.
12. Kim M.Y., Oskarsson T., Acharyya S., et al. Tumor self-seeding by circulating cancer cells. Cell 2009, 139:1315-1316.
13. Hartkopf A.D., Banys M., Krawczyk N., et al. Bone marrow versus sentinel lymph node involvement in breast cancer: a comparison of early hematogenous and early lymphatic tumor spread. Breast Cancer Res. Treat. 2012, 131:501-508.
14. Valastyan S., Weinberg R.A. Tumor metastasis: molecular insights and evolving paradigms. Cell 2011, 147:275-292.
15. Vogelstein B., Kinzler K.W. The multistep nature of cancer. Trends Genet. 1993, 9:138-141.
16. Wood L.D., Parsons D.W., Jones S., et al. The genomic landscapes of human breast and colorectal cancers. Science 2007, 318:1108-1113.
17. Egeblad M., Nakasone E.S., Werb Z. Tumors as organs: complex tissues that interface with the entire organism. Dev. Cell 2010, 18:884-901.
18. Egeblad M., Rasch M.G., Weaver V.M., et al. Dynamic interplay between the ollagen scaffold and tumor evolution. Curr. Opin. Cell Biol. 2010, 22:697-706.
19. Nguyen-Ngoc K.V., Cheung K.J., Brenot A., et al. ECM microenvironment regulates collective migration and local dissemination in normal and malignant mammary epithelium. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:E2595-E2604.
20. Whittaker C.A., Bergeron K.F., Whittle J., Brandhorst B.P., Burke R.D., Hynes R.O. The echinoderm adhesome. Dev. Biol. 2006, 1:252-266.
21. Ozbek S., Balasubramanian P.G., Chiquet-Ehrismann R., Tucker P.P., Adams J.C. The evolution of extracellular matrix. Mol. Biol. Cell 2010, 21:4300-4305.
22. Lu P., Weaver V.M., Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J. Cell Biol. 2012, 196:395-406.
23. Petrie R.J., Doyle A.D., Yamada K.M. Ramdom versus directionally persistent cell migration. Nat. Rev. Mol. Cell Biol. 2009, 10:538-549.
24. Roussos E.T., Condeelis J.S., Patsialou A. Chemotaxis in cancer. Nat. Rev. Cancer 2011, 11:573-587.
25. Valastyan S., Reinhardt F., Benaich N., et al. A pleiotropically acting microRNA miR-31, inhibits breast cancer metastasis. Cell 2009, 137:1032-1046.
26. Tan D.S., Agarwal R., Kaye S.B. Mechanisms of transcoelomic metastasis in ovarian cancer. Lancet Oncol. 2006, 7:925-934.
27. Yamaguchi H. Pathological roles of invadopodia in cancer invasion and metastasis. Eur. J. Cell Biol. 2012, 91:902-907. 10.1016/j.ejcb.2012.04.005.
28. Sibony-Benyamini H., Gil-Henn H. Invadopodia: the leading force. Eur. J. Cell Biol. 2012, 91:896-901. 10.1016/j.ejcb.2012.04.0051.
29. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
30. Polyak K., Weinberg R.A. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat. Rev. Cancer 2009, 9:265-273.
31. Sabbah M., Emami S., Redeulih G., et al. Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers. Drug Resist. Updat. 2008, 11:123-151.
32. Yang J., Weinberg R.A. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev. Cell 2008, 14:818-829.
33. Foroni C., Broggini M., Generali D., Damia G. Epithelial-mesenchymal transition and breast cancer: role, molecular mechanisms and clinical impact. Cancer Treat. Rev. 2012, 38:689-697.
34. Ota I., Li X.Y., Hu Y., Weiss S.J. Induction of a MT1-MMP and MT2-MMP dependent basement membrane transmigration program in cancer cells by Snail1. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:20318-20323.
35. Peinado H., Marin F., Cubillo E., Stark H.J., Fusenig N., Nieto M.A., Cano A. Snail and E47 repressors of E-cadherin induce distinct invasive and angiogenic properties in vivo. J. Cell Sci. 2004, 117:2827-2839.
36. Drake J.M., Strohbehn G., Bair T.B., Moreland J.G., Henry M.D. ZEB1 enhances transendothelial migration and represses the epithelial phenotype of prostate cancer cells. Mol. Biol. Cell 2009, 20:2207-2217.
37. Sun T., Zhao N., Zhao X.L., et al. Expression and functional significance of Twist1 in hepatocellular carcinoma: its role in vasculogenic mimicry. Hepatology 2010, 51:545-556.
38. van der Plujim G. Epithelial plasticity, cancer stem cells and bone formation. Bone 2011, 48:37-43.
39. Barrallo-Gimeno A., Nieto M.A. The Snail genes as inducers of cell movement and survival: implications in development and cancer. Development 2005, 132:3151-3161.
40. Sayan A.E., Griffiths T.R., Pal R., et al. SIP1 protein protects cells from DNA damage-induced apoptosis and has independent prognostic value in bladder cancer. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:14884-14889.
41. Puisieux A., Valsesia-Wittmann S. Cancer cells escape from failsafe programs in a simple Twist. Bull. Cancer 2006, 93:251-256.
42. Smit M.A., Geiger T.R., Song J.Y., Gitelman I., Peeper D.S. A Twist-Snail axis critical for TrkB-induced epithelial-mesenchymal transition-like transformation, anoikis resistance, and metastasis. Mol. Cell. Biol. 2009, 29:3722-3737.
43. Burk U., Schubert J., Wellner U., et al. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep. 2008, 9:582-589.
44. Gebeshuber C.A., Zatloukal K., Martinez J. MiR-29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis. EMBO Rep. 2009, 10:400-405.
45. Gregory P.A., Bert A.G., Paterson E.L., et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat. Cell Biol. 2008, 10:593-601.
46. Kajita M., McClinic K.N., Wade P.A. Wade, Aberrant expression of the transcription factors snail and slug alters the response to genotoxic stress. Mol. Cell. Biol. 2004, 24:7559-7566.
47. Cheng G.Z., Chan J., Wang Q., Zhang W., Sun C.D., Wang L.H. Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. Cancer Res. 2007, 67:1979-1987.
48. Roussos E.T., Keckesova Z., Haley J.D., Epstein D.M., Weinberg R.A., Condeelis J.S. AACR special conference on epithelial-mesenchymal transition and cancer progression and treatment. Cancer Res. 2010, 70:7360-7364.
49. Gradilone A., Raimondi C., Nicolazzo C., et al. Circulating tumor cells lacking cytokeratin in breast cancer: the importance of being mesenchymal. J. Cell. Mol. Med. 2011, 15:1066-1070.
50. Mego M., Mani S.A., Cristofanilli M. Molecular mechanisms of metastasis in breast cancer-clinical applications. Nat. Rev. Clin. Oncol. 2010, 7:693-701.
51. Chen W.T. Proteolytic activity of specialized surface protrusions formed at rosette contact sites of transformed cells. J. Exp. Zool. 1989, 251:167-185.
52. Yamamoto H., Sutoh M., Hatakeyama S., et al. Requirement for FBP17 in invadopodia formation by invasive bladder tumor cells. J. Urol. 2011, 185:1930-1938.
53. Stylli S.S., Kaye A.H., Lock P. Invadopodia: at the cutting edge of tumour invasion. J. Clin. Neurosci. 2008, 15:725-737.
54. Schoumacher M., Goldman R.D., Louvard D., Vignjevic D.M. Actin, microtubules, and vimentin intermediate filaments cooperate for elongation of invadopodia. J. Cell Biol. 2010, 189:541-556.
55. Coopman P.J., Do M.T., Thompson E.W., Mueller S.C. Phagocytosis of cross-linked gelatin matrix by human breast carcinoma cells correlates with their invasive capacity. Clin. Cancer Res. 1998, 4:507-515.
56. Yamaguchi H., Lorenz M., Kempiak S., et al. Molecular mechanisms of invadopodium formation: the role of the N-WASP-Arp2/3 complex pathway and cofilin. J. Cell Biol. 2005, 168:441-452.
57. Yamaguchi H., Yoshida S., Muroi E., et al. Phosphoinositide 3-kinase signaling pathway mediated by p110α regulates invadopodia formation. J. Cell Biol. 2011, 193:1275-1288.
58. Yamaguchi H., Wyckoff J., Condeelis J. Cell migration in tumors. Curr. Opin. Cell Biol. 2005, 17:559-564.
59. Friedl P., Alexander S. Cancer invasion and the microenvironment: plasticity and reciprocity. Cell 2011, 147:992-1009.
60. Tolde O., Rosel D., Vesely P., Folk P., Brabek J. The structure of invadopodia in a complex 3D environment. Eur. J. Cell Biol. 2010, 89:674-680.
61. Parekh A., Ruppender N.S., Branch K.M., et al. Sensing and modulation of invadopodia across a wide range of rigidities. Biophys. J. 2011, 100:573-582.
62. Eckert M.A., Lwin T.M., Chang A.T., et al. Twist1-induced invadopodia formation promotes tumor metastasis. Cancer Cell 2011, 19:372-386.
63. Gligorijevic B., Wyckoff J., Yamaguchi H., Wang Y., Roussos E.T., Condeelis J. N-WASP-mediated invadopodium formation is involved in intravasation and lung metastasis of mammary tumors. J. Cell Sci. 2012, 125:724-734.
64. Morishige M., Hashimoto S., Ogawa E., et al. GEP100 links epidermal growth factor receptor signalling to Arf6 activation to induce breast cancer invasion. Nat. Cell Biol. 2008, 10:85-92.
65. Muralidharan-Chari V., Hoover H., Clancy J., et al. ADP-ribosylation factor 6 regulates tumorigenic and invasive properties in vivo. Cancer Res. 2009, 69:2201-2209.
66. Wang W., Mouneimne G., Sidani M., et al. The activity status of cofilin is directly related to invasion, intravasation, and metastasis of mammary tumors. J. Cell Biol. 2006, 173:395-404.
67. Philippar U., Roussos E.T., Oser M., et al. A Mena invasion isoform potentiates EGF-induced carcinoma cell invasion and metastasis. Dev. Cell 2008, 15:813-828.
68. Li S.Y., Rong M., Grieu F., Iacopetta B. PIK3CA mutations in breast cancer are associated with poor outcome. Breast Cancer Res. Treat. 2006, 96:91-95.
69. Buday L., Downward J. Roles of cortactin in tumor pathogenesis. Biochim. Biophys. Acta 2007, 1775:263-273.
70. Burgermeister E., Liscovitch M., Rocken C., Schmid R.M., Ebert M.P. Caveats of caveolin-1 in cancer progression. Cancer Lett. 2008, 268:187-201.
71. Machesky L.M., Li A. Fascin: invasive filopodia promoting metastasis. Commun. Integr. Biol. 2010, 3:263-270.
72. Seiki M. Membrane-type 1 matrix metalloproteinase: a key enzyme for tumor invasion. Cancer Lett. 2003, 194:1-11.
73. Ayala I., Giacchetti G., Caldieri G. Faciogenital dysplasia protein Fgd1 regulates invadopodia biogenesis and extracellular matrix degradation and is up-regulated in prostate and breast cancer. Cancer Res. 2009, 69:747-752.
74. Stylli S.S., I S.T., Kaye A.H., Lock P. Prognostic significance of Tks5 expression in gliomas. J. Clin. Neurosci. 2012, 19:436-442.
75. Oser M., Dovas A., Cox D., Condeelis J. Nck1 and Grb2 localization patterns can distinguish invadopodia from podosomes. Eur. J. Cell Biol. 2011, 90:181-188.
76. Dirat B., Bochet L., Dabek M., et al. Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion. Cancer Res. 2011, 71:2455-2465.
77. Giampieri S., Manning C., Hooper S., Jones L., Hill C.S., Sahai E. Localized and reversible TGF beta signaling switches breast cancer cells from cohesive to single cell motility. Nat. Cell Biol. 2009, 11:1287-1296.
78. Wyckoff J.B., Wang Y., Lin E.Y., Li J.F., et al. Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res. 2007, 67:2649-2656.
79. Gupta G.P., Nguyen D.X., Chiang A.C., et al. Mediators of vascular remodeling co-opted for sequential steps in lung metastasis. Nature 2007, 446:765-770.
80. Carmeliet P., Jain R.K. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat. Rev. Drug Discov. 2011, 10:417-427.
81. Guo W., Giancotti F.G. Integrin signaling during tumour progression. Nat. Rev. Mol. Cell Biol. 2004, 5:816-826.
82. Schafer Z.T., Grassian A.R., Song L., et al. Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature 2009, 461:109-113.
83. Douma S., Van Laar T., Zevenhoven J., Meuwissen R., Van Garderen E., Peeper D.S. Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature 2004, 430:1034-1039.
84. Remmerbach T.W., Wottawah F., Dietrich J., Lincoln B., Wittekind C., Guck J. Oral cancer diagnosis by mechanical phenotyping. Cancer Res. 2009, 69:1728-1732.
85. Joyce J.A., Pollar J.W. Microenviromental regulation of metastasis. Nat. Rev. Cancer 2009, 9:239-252.
86. Matrone M.A., Whipple R.A., Thompson K., et al. Metastatic breast tumors express increased tau, which promotes microtentacle formation and the reattachment of detached breast tumor cells. Oncogene 2010, 29:3217-3227.
87. Korb T., Schluter K., Enns A., et al. Integrity of actin fibers and microtubules influences metastatic tumor cell adhesion. Exp. Cell Res. 2004, 299:236-247.
88. Pantel K., Alix-Panabières C., Riethdorf S. Cancer micrometastases. Nat. Rev. Clin. Oncol. 2009, 6:339-351.
89. Friedl P., Wolf K. Tumor-cell invasion and migration: diversity and escape mechanisms. Nat. Rev. Cancer 2003, 3:362-374.
90. Gupta G.P., Massagué J. Cancer metastasis: building a framework. Cell 2006, 127:679-695.
91. Brown D.M., Ruoslahti E. Metadherin, a cell surface protein in breast tumors that mediates lung metastasis. Cancer Cell 2004, 5:365-374.
92. Lu X., Kang Y. Organotropism of breast cancer metastasis. J. Mammary Gland Biol. Neoplasia 2007, 12:153-162.
93. Minn A.J., Kang Y., Serganova I., et al. Distinct organ specific metastatic potential of individual breast cancer cells and primary tumors. J. Clin. Invest. 2005, 115:44-55.
94. Muller A., Homey B., Soto H., et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410:50-56.
95. Wang J., Loberg R., Taichman R.S. The pivotal role of cxcl12 (sdf-1)/cxcr4 axis in bone metastasis. Cancer Metastasis Rev. 2006, 25:573-587.
96. Lorusso G., Rüegg C. New insights into the mechanisms of organ-specific breast cancer metastasis. Semin. Cancer Biol. 2012, 22:226-233.
97. Nguyen D.X., Bos P.D., Massagué J. Metastasis: from dissemination to organ-specific colonization. Nat. Rev. Cancer 2009, 9:274-284.
98. Shibue T., Weinberg R.A. Metastatic colonization: settlement, adaptation and propagation of tumor cells in a foreign tissue environment. Semin. Cancer Biol. 2011, 21:99-106.
99. Bockhorn M., Jain R.K., Munn L.L. Active versus passive mechanisms in metastasis: do cancer cells crawl into vessels, or are they pushed?. Lancet Oncol. 2007, 8:444-448.
100. Padua D., Zhang X.H., Wang Q., et al. TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 2008, 133:66-77.
101. Weis S., Cui J., Barnes L., Cheresh D. Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis. J. Cell Biol. 2004, 167:223-229.
102. Huang Y., Song N., Ding Y., et al. Pulmonary vascular destabilization in the premetastatic phase facilitates lung metastasis. Cancer Res. 2009, 69:7529-7537.
103. Hiratsuka S., Goel S., Kamoun W.S., et al. Endothelial focal adhesion kinase mediates cancer cell homing to discrete regions of the lungs via E-selectin up regulation. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:3725-3730.
104. Gupta G.P., Minn A.J., Kang Y., et al. Identifying site-specific metastasis genes and functions. Cold Spring Harb. Symp. Quant. Biol. 2005, 70:149-158.
105. Nguyen D.X., Massague J. Genetic determinants of cancer metastasis. Nat. Rev. Genet. 2007, 8:341-352.
106. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889, 133:571-573.
107. Sethi N., Kang Y. Unravelling the complexity of metastasis-molecular understanding and targeted therapies. Nat. Rev. Cancer 2011, 11:735-748.
108. Goss P.E., Chambers A.F. Does tumour dormancy offer a therapeutic target?. Nat. Rev. Cancer 2010, 10:871-877.
109. Steeg P.S., Theodorescu D. Metastasis: a therapeutic target for cancer. Nat. Clin. Pract. Oncol. 2008, 5:206-219.
110. Pierga J.Y., Bonneton C., Vincent-Salomon A., et al. Clinical significance of immunocytochemical detection of tumor cells using digital microscopy in peripheral blood and bone marrow of breast cancer patients. Clin. Cancer Res. 2004, 10:1392-1400.
111. Redding W.H., Coombes R.C., Monaghan P., et al. Detection of micrometastases in patients with primary breast cancer. Lancet 1983, 2:1271-1274.
112. Alunni-Fabbroni M., Sandri M.T. Circulating tumour cells in clinical practice: methods of detection and possible characterization. Methods 2010, 50:289-297.
113. Si H., Sun X., Chen Y., Cao Y., Chen S., Wang H., Hu C. Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer. J. Cancer Res. Clin. Oncol. 2013, 139:223-229. http://link.springer.com/article/10.1007%2Fs00432-012-1315-y.
114. Madhavan D., Zucknick M., Wallwiener M., et al. Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer. Clin. Cancer Res. 2012, 18:5972-5982.
115. Cen P., Ni X., Yang J., Graham D.Y., Li M. Circulating tumor cells in the diagnosis and management of pancreatic cancer. Biochim. Biophys. Acta 2012, 1826:350-356.
116. Yu M., Stott S., Toner M., Maheswarran S., Haber D.A. Circulating tumor cells: approaches to isolation and characterization. J. Cell Biol. 2011, 192:373-382.
117. Sun Y.F., Yang X.R., Zhou J., Qiu S.J., Fan J., Xu Y. Circulating tumor cells: advances in detection methods, biological issues, and clinical relevance. J. Cancer Res. Clin. Oncol. 2011, 137:1151-1173.
118. Vona G., Sabile A., Louha M., et al. Isolation by size of epithelial tumor cells: a new method for the immunomorphological and molecular characterization of circulating tumor cells. Am. J. Pathol. 2000, 156:57-63.
119. Busch R., Cesar D., Higuera-Alhino D., Gee T., Hellerstein M.K., McCune J.M. Isolation of peripheral blood CD4(+) T cells using RosetteSep and MACS for studies of DNA turnover by deuterium labeling. J. Immunol. Methods 2004, 286:97-109.
120. Hayes G.M., Busch R., Voogt J., et al. Isolation of malignant B cells from patients with chronic lymphocytic leukemia (CLL) for analysis of cell proliferation: validation of a simplified method suitable for multi-center clinical studies. Leuk. Res. 2010, 34:809-815.
121. Desitter I., Guerrouahen B.S., Benali-Furet N., et al. A new device for rapid isolation by size and characterization of rare circulating tumor cells. Anticancer Res. 2011, 31:427-442.
122. Rosenberg R., Gertler R., Friederichs J., et al. Comparison of two density gradient centrifugation systems for the enrichment of disseminated tumor cells in blood. Cytometry 2002, 49:150-158.
123. Witzig T.E., Bossy B., Kimlinger T., et al. Detection of circulating cytokeratin-positive cells in the blood of breast cancer patients using immunomagnetic enrichment and digital microscopy. Clin. Cancer Res. 2002, 8:1085-1091.
124. Trzpis M., McLaughlin P.M., de Leij L.M., Harmsen M.C. Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule. Am. J. Pathol. 2007, 171:386-395.
125. Gertler R., Rosenberg R., Fuehrer K., Dahm M., Nekarda H., Siewert J.R. Detection of circulating tumor cells in blood using an optimized density gradient centrifugation. Recent Results Cancer Res. 2003, 162:149-155.
126. Iinuma H., Okinaga K., Adachi M., et al. Detection of tumor cells in blood using CD45 magnetic cell separation followed by nested mutant allele-specific amplification of p53 and K-ras genes in patients with colorectal cancer. Int. J. Cancer 2000, 89:337-344.
127. Siewert C., Herber M., Hunzelmann N., et al. Rapid enrichment and detection of melanoma cells from peripheral blood mononuclear cells by a new assay combining immunomagnetic cell sorting and immunocytochemical staining. Recent Results Cancer Res. 2001, 158:51-60.
128. de Cremoux P., Extra J.M., Denis M.G., et al. Detection of MUC1-expressing mammary carcinoma cells in the peripheral blood of breast cancer patients by real-time polymerase chain reaction. Clin. Cancer Res. 2000, 6:3117-3122.
129. Sleijfer S., Gratama J.W., Siewerts A.M., Kraan J., Martens J.W., Foekens J.A. Circulating tumour cell detection on its way to routine diagnostic implementation?. Eur. J. Cancer 2007, 43:2645-2650.
130. Tewes M., Aktas B., Welt A., et al. Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies. Breast Cancer Res. Treat. 2009, 115:581-590.
131. Neurauter A.A., Bonyhadi M., Lien E., et al. Cell isolation and expansion using dynabeads. Adv. Biochem. Eng. Biotechnol. 2007, 106:41-73.
132. Peters C.E., Woodside S.M., Eaves A.C. Isolation of subsets of immune cells. Methods Mol. Biol. 2005, 302:95-116.
133. Naume B., Borgen E., Beiske K., et al. Immunomagnetic techniques for the enrichment and detection of isolated breast carcinoma cells in bone marrow and peripheral blood. J. Hematother. 1997, 6:103-114.
134. Allard W.J., Matera J., Miller M.C., et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin. Cancer Res. 2004, 10:6897-6904.
135. Cristofanilli M., Budd G.T., Ellis M.J., et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med. 2004, 351:781-791.
136. Cristofanilli M. The biological information obtainable from circulating tumor cells. Breast 2009, 18:S38-S40.
137. Nagrath S., Sequist L.V., Maheswaran S., et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 2007, 450:1235-1239.
138. Schulz M.J., Shanov V.N., Yun Y. Nanomedicine: Design of Particles, Sensors, Motors, Implants, Robots, and Devices 2009, Artech House, London.
139. Stott S.L., Hsu C.H., Tsukrov D.I. Isolation of circulating tumor cells using a micorvortex-generating herringbone-chip. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:18392-18397.
140. Huang L.R., Cox E.C., Austin R.H., Sturm J.C. Continuous particle separation through deterministic lateral displacement. Science 2004, 304:987-990.
141. Gascoyne P.R.C., Wang X.B., Huang Y., Becker F.F. Dielectrophoretic separation of cancer cells from blood. IEEE Trans. Ind. Appl. 1997, 33:670-678.
142. Huang Y., Wang X.B., Becker F.F., Gascoyne P.R. Introducing dielectrophoresis as a new force field for field-flow fractionation. Biophys. J. 1997, 73:1118-1129.
143. Markx G.H., Rousselet J., Pethig R. DEP-FFF: field-flow fractionation using non-uniform electric fields. J. Liq. Chromatogr. Relat. Technol. 1997, 20:2857-2872.
144. Fleischer R.L. Cancer filter déjà vu. Science 2007, 318:1864.
145. Lankiewicz S., Rivero B.G., Bócher O. Quantitative real-time RT-PCR of disseminated tumor cells in combination with immunomagnetic cell enrichment. Mol. Biotechnol. 2006, 34:15-27.
146. Andreopoulou E., Yang L.Y., Rangel K.M., et al. Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen Adna Test BreastCancer Select/DetectTM versus Veridez Cell SearchTM system. Int. J. Cancer 2012, 130:1590-1597.
147. Fehm T., Hoffmann O., Aktas B., et al. Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. Breast Cancer Res. 2009, 11:R59.
148. Riethdorf S., Muller V., Zhang L., et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin. Cancer Res. 2010, 16:2634-2645.
149. Pestrin M., Bessi S., Galardi F., et al. Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients. Breast Cancer Res. Treat. 2009, 118:523-530.
150. Reuben J.M., Lee B.N., Li C., et al. Circulating tumor cells and biomarkers:implications for personalized targeted treatments for metastasic breast cancer. Breast J. 2010, 16:327-330.
151. Lu J., Fan T., Zhao Q., et al. Isolation of circulating epithelial and tumor progenitor cells with an invasive phenotype from breast cancer patients. Int. J. Cancer 2010, 126:669-683.
152. Kojima T., Hashimoto Y., Watanabe Y., et al. A simple biological imaging, system for detecting viable human circulating tumor cells. J. Clin. Invest. 2009, 119:3172-3181.
153. Fong S.M., Lee M.K., Adusumilli P.S., Kelly K.J. Fluorescence-expressing viruses allow rapid identification and separation of rare tumor cells in spiked samples of human whole blood. Surgery 2009, 146:498-505.
154. Chung Y.K., Reboud J., Lee K.C., et al. An electrical biosensor for the detection of circulating tumor cells. Biosens. Bioelectron. 2011, 26:2520-2526.
155. Marrinucci D., Bethel K., Kolatkar A., et al. Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers. Phys. Biol. 2012, 9:016003.
156. Takao M., Takeda K. Enumeration, characterization, and collection of intact circulating tumor cells by cross contamination-free flow cytometry. Cytometry A 2011, 79:107-117.
157. Mostert B., Sleijfer S., Foekens J.A., Gratama J.W. Circulating tumor cells (CTCS): detection methods and their clinical relevance in breast cancer. Cancer Treat. Rev. 2009, 35:463-474.
158. Woelfle U., Cloos J., Sauter G., et al. Molecular signature associated with bone marrow micrometastasis in human breast cancer. Cancer Res. 2003, 63:5679-5684.
159. Willipinski-Stapelfeldt B., Riethdorf S., Assmann V., et al. Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells. Clin. Cancer Res. 2005, 11:8006-8014.
160. Paterlini-Brechot P., Benali N.L. Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Lett. 2007, 253:180-204.
161. Zieglschmid V., Hollmann C., Gutierrez B., Albert W., Strothoff D., Gross E., Böcher O. Combination of immunomagnetic enrichment with multiplex RT-PCR analysis for the detection of disseminated tumor cells. Anticancer Res. 2005, 25:1803-1810.
162. Went P.T., Lugli A., Meier S., et al. Frequent EpCam protein expression in human carcinomas. Hum. Pathol. 2004, 35:122-128.
163. Wang F., Flanagan J., Su N., et al. RNAScope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. J. Mol. Diagn. 2012, 14:22-29.
164. Affymetrix & Panomics Solutions, Data Sheet: QuantiGene ViewRNA CTC Platform. Consulted 28.12.12. http://www.panomics.com/products/rna-in-situ-analysis/ctc-platform/literature-support.
165. Player A.N., Shen L.P., Kenny D., Antao V.P., Kolberg J.A. Single-copy gene detection using branched DNA (bDNA) in situ hybridization. J. Histochem. Cytochem. 2001, 49:603-612.
166. Yu M., Ting D.T., Stott S.L., et al. RNA sequencing of pancreatic circulating tumour cells implicates WNT signaling in metastasis. Nature 2012, 487:510-513.
167. Wang L., Wang Y., Liu Y., Cheng M., Wu X., Wei H. Flow cytometric analysis of CK19 expression in the peripheral blood of breast carcinoma patients: relevance for circulating tumor cell detection. J. Exp. Clin. Cancer Res. 2009, 28:57.
168. Hu Y., Fan L., Zheng J., Cui R., Liu W., He Y., Li X., Huang S. Detection of circulating tumor cells in breast cancer patients utilizing multiparameter flow cytometry and assessment of the prognosis of patients in different CTCs levels. Cytometry A 2010, 77:213-219.
169. Hsieh H.B., Marrinucci D., Bethel K., et al. High speed detection of circulating tumor cells. Biosens. Bioelectron. 2006, 21:1893-1899.
170. Krivacic R.T., Ladanyi A., Curry D.N., et al. A rare-cell detector for cancer. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:10501-10504.
171. Somlo G., Lau S.K., Frankel P., et al. Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology. Breast Cancer Res. Treat. 2011, 128:155-163.
172. Alix-Panabières C., Vendrell J.P., Pellé O., et al. Detection and characterization of putative metastatic precursor cells in cancer patients. Clin. Chem. 2007, 53:537-539.
173. Alix-Panabières C., Vendrell J.P., Slijper M., et al. Full-length cytokeratin-19 is released by human tumor cells: a potential role in metastatic progression of breast cancer. Breast Cancer Res. 2009, 11:R39.
174. Pachmann K., Camara O., Kavallaris A., et al. Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse. J. Clin. Oncol. 2008, 26:1208-1215.
175. Pachmann K., Clement J.H., Schneider C.P., et al. Standardized quantification of circulating peripheral tumor cells from lung and breast cancer. Clin. Chem. Lab. Med. 2005, 43:617-627.
176. Kraeft S.K., Sutherland R., Gravelin L., et al. Detection and analysis of cancer cells in blood and bone marrow using a rare event imaging system. Clin. Cancer Res. 2000, 6:434-442.
177. Mansi J.L., Mesker W.E., McDonnell T., Van Driel-Kulker A.M., Ploem J.S., Coombes R.C. Automated screening for micrometastases in bone marrow smears. J. Immunol. Methods 1988, 112:105-111.
178. Mesker W.E., vd Burg J.M., Oud P.S., et al. Detection of immunocytochemically stained rare events using image analysis. Cytometry 1994, 17:209-215.
179. Van der Auwera I., Peeters D., Benoy I.H., et al. Circulating tumour cell detection: a direct comparison between the Cell Search System, the AdnaTest and CK-19/mammaglobin RT-PCR in patients with metastatic breast cancer. Br. J. Cancer 2010, 102:276-284.
180. Smith B.M., Slade M.J., English H., et al. Response of circulating tumor cells to systemic therapy in patients with metastatic breast cancer: comparison of quantitative polymerase chain reaction and immunocytochemical techniques. J. Clin. Oncol. 2000, 18:1432-1439.
181. Lambrechts A.C., Bosma A.J., Klaver S.G., et al. Comparison of immunocytochemistry, reverse transcriptase polymerase chain reaction, and nucleic acid sequence-based amplification for the detection of circulating breast cancer cells. Breast Cancer Res. Treat. 1999, 56:219-231.
182. Xenidis N., Perraki M., Kafousi M., et al. Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients. J. Clin. Oncol. 2006, 24:3756-3762.
183. Pantel K., Brakenhoff R.H., Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat. Rev. Cancer 2008, 8:329-340.
184. Ignatiadis M., Xenidis N., Perraki M., et al. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer. J. Clin. Oncol. 2007, 25:5194-5202.
185. Stathopoulou A., Gizi A., Perraki M., et al. Real-time quantification of CK-19 mRNA-positive cells in peripheral blood of breast cancer patients using the lightcycler system. Clin. Cancer Res. 2003, 9:5145-5151.
186. Nolan T., Hands R.E., Bustin S.A., et al. Quantification of mRNA using real-time RT-PCR. Nat. Protoc. 2006, 1:1559-1582.
187. Zach O., Kasparu H., Krieger O., Hehenwarter W., Girschikofsky M., Lutz D. Detection of circulating mammary carcinoma cells in the peripheral blood of breast cancer patients via a nested reverse transcriptase polymerase chain reaction assay for mammaglobin mRNA. J. Clin. Oncol. 1999, 17:2015-2019.
188. Shen C., Hu L., Xia L., Li Y. The detection of circulating tumor cells of breast cancer patients by using multimarker (Survivin, hTERT and hMAM) quantitative real-time PCR. Clin. Biochem. 2009, 42:194-200.
189. Xi L., Nicastri D.G., El-Hefnawy T., Hughes S.J., Luketich J.D., Godfrey T.E. Optimal markers for real-time quantitative reverse transcription PCR detection of circulating tumor cells from melanoma, breast, colon, esophageal, head and neck, and lung cancers. Clin. Chem. 2007, 53:1206-1215.
190. Meng S., Tripathy D., Frenkel E.P., et al. Circulatint tumor cells in patients with breast cancer dormancy. Clin. Cancer Res. 2004, 10:8152-8162.
191. Graves H., Czerniecki B.J. Circulating tumor cells in breast cancer patients: an evolving role in patients and disease progression. Patholog. Res. Int. 2011, 2011:621090.
192. Wan T.S., Ma E.S. Molecular cytogenetics: an indispensable tool for cancer diagnosis. Chang Gung Med. J. 2012, 35:96-110.
193. Kallioniemi A., Kallioniemi O.P., Sudar D., et al. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science 1992, 258:818-821.
194. Klein C.A., Blankenstein T.J., Schmidt-Kittler O., et al. Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet 2002, 360:683-689.
195. Freeman J.L., Perry G.H., Feuk L., et al. Copy number variation: new insights in genome diversity. Genome Res. 2006, 16:949-961.
196. Peeper D., Berns A. Cross-species oncogenomics in cancer gene identification. Cell 2006, 125:1230-1233.
197. Nakagawa T., Martinez S.R., Goto Y., et al. Detection of circulating tumor cells in early-stage breast cancer metastasis to axillary lymph nodes. Clin. Cancer Res. 2007, 13:4105-4110.
198. Upko O.C., Flanagan J.J., Ma X.J., Luo Y., Thorstad W.L., Lewis J.S. High-risk human papillomavirus E6/E7 mRNA detection by a novel in situ hybridization assay strongly correlates with p16 expression and patient outcomes in oropharyngeal squamous cell carcinoma. Am. J. Surg. Pathol. 2011, 35:1343-1350.
199. Payne R.E., Wang F., Su N., et al. Viable circulating tumour cell detection using multiplex RNA in situ hybridization predicts progression-free survival in metastatic breast cancer patients. Br. J. Cancer 2012, 106:1790-1797.
200. Bushnell S., Budde J., Catino T., et al. ProbeDesigner: for the design of probesets for branched DNA (bDNA) signal amplification assays. Bioinformatics 1999, 15:348-355.
201. Situma C., Hashimoto M., Soper S.A. Merging microfluidics with microarray-based bioassays. Biomol. Eng. 2006, 23:213-231.
202. Zhang Y., Coyne M.Y., Will S.G., Levenson C.H., Kawasaki E.S. Single-base mutational analysis of cancer and genetic diseases using membrane bound modified oligonucleotides. Nucleic Acids Res. 1991, 19:3929-3933.
203. McClain M.A., Culbertson C.T., Jacobson S.C., Allbritton N.L., Sims C.E., Ramsey J.M. Microfluidic devices for the high-throughput chemical analysis of cells. Anal. Chem. 2003, 75:5646-5655.
204. Pease A.C., Solas D., Sullivan E.J., Cronin M.T., Holmes C.P., Fodor S.P. Light-generated oligonucleotide arrays for rapid DNA sequence analysis. Proc. Natl. Acad. Sci. U.S.A. 1994, 91:5022-5026.
205. Postier B.L., Wang H.L., Singh A., et al. The construction and use of bacterial DNA microarrays based on an optimized two-stage PCR strategy. BMC Genomics 2003, 4:23.
206. Bussow K., Nordhoff E., Lübbert C., Lehrach H., Walter G. A human cDNA library for high-throughput protein expression screening. Genomics 2000, 65:1-8.
207. MacBeath G., Schreiber S.L. Printing proteins as microarrays for highthroughput function determination. Science 2000, 289:1760-1763.
208. Baner J., Isaksson A., Waldenstroem E., Jarvius J., Landegren U., Nilsson M. Parallel gene analysis with allele-specific padlock probes and tag microarrays. Nucleic Acids Res. 2003, 31:e103.
209. González Roca E., Garcia Albéniz X., Rodríguez-Mulero S., Gomis R.R., Kornacker K., Auer H. Accurate expression profiling of very small cell populations. PLoS One 2010, 5:e14418.
210. Markou A., Strati A., Malamos N., Georgoulias V., Lianidou E. Molecular characterization of circulating tumor cells in breast cancer by a liquid bead array hybridization assay. Clin. Chem. 2011, 57:421-430.
211. Brandt B., Roetger A., Heidl S., et al. Isolation of blood-borne epithelium-derived c-erbB-2 oncoprotein-positive clustered cells from the peripheral blood of breast cancer patients. Int. J. Cancer 1998, 76:824-828.
212. Kim S.J., Ikeda N., Shiba E., Takamura Y., Noguchi S. Detection of breast cancer micrometastases in peripheral blood using immunomagnetic separation and immunocytochemistry. Breast Cancer 2001, 8:63-69.
213. Krag D.N., Ashikaga T., Moss T.J., et al. Breast cancer cells in the blood: a pilot study. Breast J. 1999, 5:354-358.
214. Reinholz M.M., Nibbe A., Jonart L.M., et al. Evaluation of a panel of tumor markers for molecular detection of circulating cancer cells in women with suspected breast cancer. Clin. Cancer Res. 2005, 11:3722-3732.
215. Zehentner B.K., Persing D.H., Deme A., et al. Mammaglobin as a novel breast cancer biomarker: multigene reverse transcription-PCR assay and sandwich ELISA. Clin. Chem. 2004, 50:2069-2076.
216. Deng G., Herrler M., Burgess D., Manna E., Krag D., Burke J.F. Enrichment with anti-cytokeratin alone or combined with anti-EpCAM antibodies significantly increases the sensitivity for circulating tumor cell detection in metastatic breast cancer patients. Breast Cancer Res. 2008, 10:R69.
217. Balic M., Dandachi N., Hofmann G., et al. Comparison of two methods for enumerating circulating tumor cells in carcinoma patients. Cytometry B Clin. Cytom. 2005, 68:25-30.
218. Fehm T., Becker S., Duerr-Stoerzer S., et al. Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status. Breast Cancer Res. 2007, 9:R74.
219. Bauernhofer T., Zenahlik S., Hofmann G., et al. Association of disease progression and poor overall survival with detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer. Oncol. Rep. 2005, 13:179-184.
220. Taback B., Chan A.D., Kuo C.T., et al. Detection of occult metastatic breast cancer cells in blood by a multimolecular marker assay: correlation with clinical stage of disease. Cancer Res. 2001, 61:8845-8850.
221. Hu X.C., Chow L.W. Detection of circulating breast cancer cells with multiplemarker RT-PCR assay. Anticancer Res. 2001, 21:421-424.
222. Hoon D.S., Sarantou T., Doi F., et al. Detection of metastatic breast cancer by beta-hCG polymerase chain reaction. Int. J. Cancer 1996, 69:369-374.
223. Meng S., Tripathy D., Shete S., et al. uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:17361-17365.
224. Masuda T.A., Kataoka A., Ohno S., et al. Detection of occult cancer cells in peripheral blood and bone marrow by quantitative RT-PCR assay for cytokeratin-7 in breast cancer patients. Int. J. Oncol. 2005, 26:721-730.
225. Felton T., Harris G.C., Pinder S.E., et al. Identification of carcinoma cells in peripheral blood samples of patients with advanced breast carcinoma using RT-PCR amplification of CK7 and MUC1. Breast 2004, 13:35-41.
226. Alix-Panabières C., Brouillet J.P., Fabbro M., et al. Characterization and enumeration of cells secreting tumor markers in the peripheral blood of breast cancer patients. J. Immunol. Methods 2005, 299:177-188.
227. Jotsuka T., Okumura Y., Nakano S., et al. Persistent evidence of circulating tumor cells detected by means of RT-PCR for CEA mRNA predicts early relapse: a prospective study in node-negative breast cancer. Surgery 2004, 135:419-426.
228. Mitas M., Mikhitarian K., Walters C., et al. Quantitative real-time RT-PCR detection of breast cancer micrometastasis using a multigene marker panel. Int. J. Cancer 2001, 93:162-171.
229. de Bono J.S., Attard G., Adjei A., et al. Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor. Clin. Cancer Res. 2007, 13:3611-3616.
230. Kruger W., Krzizanowski C., Holweg M., et al. Reverse transcriptase/polimerase chain reaction detection of cytokeratin-19 mRNA in bone marrow and blood of breast cancer patients. J. Cancer Res. Clin. Oncol. 1996, 122:679-686.
231. Stathopoulou A., Vlachonikolis I., Mavroudis D., et al. Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. J. Clin. Oncol. 2002, 20:3404-3412.
232. Stathopoulos E.N., Sanidas E., Kafousi M., et al. Detection of CK-19 mRNApositive cells in the peripheral blood of breast cancer patients with histologically and immunohistochemically negative axillary lymph nodes. Ann. Oncol. 2005, 16:240-246.
233. Stathopoulou A., Mavroudis D., Perraki M., et al. Molecular detection of cancer cells in the peripheral blood of patients with breast cancer: comparison of CK-19, CEA and maspin as detection markers. Anticancer Res. 2003, 23:1883-1890.
234. Grunewald K., Haun M., Urbanek M., et al. Mammaglobin gene expression: a superior marker of breast cancer cells in peripheral blood in comparison to epidermal-growth-factor receptor and cytokeratin-19. Lab. Invest. 2000, 80:1071-1077.
235. Silva H.A., Abraul E., Raimundo D., et al. Molecular detection of EGFRvIII-positive cells in the peripheral blood of breast cancer patients. Eur. J. Cancer 2006, 42:2617-2622.
236. Gradilone A., Gazzaniga P., Silvestri I., et al. Detection of CK19, CK20 and EGFR mRNAs in peripheral blood of carcinoma patients: correlation with clinical stage of disease. Oncol. Rep. 2003, 10:217-222.
237. Bosma A.J., Weigelt B., Lambrechts A.C., et al. Detection of circulating breast tumor cells by differential expression of marker genes. Clin. Cancer Res. 2002, 8:1871-1877.
238. Quintela-Fandino M., Lopez J.M., Hitt R., et al. Breast cancer-specific mRNA transcripts presence in peripheral blood after adjuvant chemotherapy predicts poor survival among high-risk breast cancer patients treated with high-dose chemotherapy with peripheral blood stem cell support. J. Clin. Oncol. 2006, 24:3611-3618.
239. Ignatiadis M., Kallergi G., Ntoulia M., et al. Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription- PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer. Clin. Cancer Res. 2008, 14:2593-2600.
240. Wasserman L., Dreilinger A., Easter D., Wallace A. A seminested RT-PCR assay for HER2/neu: initial validation of a new method for the detection of disseminated breast cancer cells. Mol. Diagn. 1999, 4:21-28.
241. Apostolaki S., Perraki M., Pallis A., et al. Circulating HER2 mRNA-positive cells in the peripheral blood of patients with stage I and II breast cancer after the administration of adjuvant chemotherapy: evaluation of their clinical relevance. Ann. Oncol. 2007, 18:851-858.
242. Berois N., Varangot M., Aizen B., et al. Molecular detection of cancer cells in bone marrow and peripheral blood of patients with operable breast cancer. Comparison of CK19, MUC1 and CEA using RT-PCR. Eur. J. Cancer 2000, 36:717-723.
243. Brown N.M., Stenzel T.T., Friedman P.N., Henslee J., Huper G., Marks J.R. Evaluation of expression based markers for the detection of breast cancer cells. Breast Cancer Res. Treat. 2006, 97:41-47.
244. Baker M.K., Mikhitarian K., Osta W., et al. Molecular detection of breast cancer cells in the peripheral blood of advanced-stage breast cancer patients using multimarker real-time reverse transcription-polymerase chain reaction and a novel porous barrier density gradient centrifugation technology. Clin. Cancer Res. 2003, 9:4865-4871.
245. Wulf G.G., Jürgens B., Liersch T., et al. Reverse transcriptase/polymerase chain reaction analysis of parathyroid hormone-related protein for the detection of tumor cell dissemination in the peripheral blood and bone marrow of patients with breast cancer. J. Cancer Res. Clin. Oncol. 1997, 123:514-521.
246. Fanger G.R., Houghton R.L., Retter M.W., et al. Detection of mammaglobin in the sera of patients with breast cancer. Tumour Biol. 2002, 23:212-221.
247. Bossolasco P., Ricci C., Farina G., et al. Detection of micrometastatic cells in breast cancer by RT-pCR for the mammaglobin gene. Cancer Detect. Prev. 2002, 26:60-63.
248. Lin Y.C., Wu Chou Y.H., Liao I.C., Cheng A.J. The expression of mammaglobin mRNA in peripheral blood of metastatic breast cancer patients as an adjunct to serum tumor markers. Cancer Lett. 2003, 191:93-99.
249. Suchy B., Austrup F., Driesel G., et al. Detection of mammaglobin expressing cells in blood of breast cancer patients. Cancer Lett. 2000, 158:171-178.
250. López-Guerrero J.A., Gilabert P.B., González E.B., et al. Use of reverse-transcriptase polymerase chain reaction (RT-PCR) for carcinoembryonic antigen, cytokeratin 19, and maspin in the detection of tumor cells in leukapheresis products from patients with breast cancer: comparison with immunocytochemistry. J. Hematother. 1999, 8:53-61.
251. Corradini P., Voena C., Astolfi M., et al. Maspin and mammaglobin genes are specific markers for RT-PCR detection of minimal residual disease in patients with breast cancer. Ann. Oncol. 2001, 12:1693-1698.
252. Luppi M., Morselli M., Bandieri E., et al. Sensitive detection of circulating breast cancer cells by reverse-transcriptase polymerase chain reaction of maspin gene. Ann. Oncol. 1996, 7:619-624.
253. Mercatali L., Valenti V., Calistri D., et al. RT-PCR determination of maspin and mammaglobin B in peripheral blood of healthy donors and breast cancer patients. Ann. Oncol. 2006, 17:424-428.
254. Yie S.M., Luo B., Ye N.Y., Xie K., Ye S.R. Detection of survivin-expressing circulating cancer cells in the peripheral blood of breast cancer patients by a RT-PCR ELISA. Clin. Exp. Metastasis 2006, 23:279-289.
255. Guttery D.S., Blighe K., Page K., et al. Hide and seek: tell-tale signs of breast cancer lurking in the blood. Cancer Metastasis. Rev. 2012, 23108389.
256. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 1971, 285:1182-1186.
257. Allan A.L., Keeney M. Circulating tumor cell analysis: technical and statistical considerations for application to the clinic. J. Oncol. 2010, 2010:426218.
258. Subarsky P., Hill R.P. The hypoxic tumour microenvironment and metastatic progression. Clin. Exp. Metastasis 2003, 20:237-250.
259. Brooks S.A., Lomax-Browne H.J., Carter T.M., Kinch C.E., Hall D.M. Molecular interactions in cancer cell metastasis. Acta Histochem. 2010, 112:3-25.
260. Cristofanilli M., Hayes D.F., Budd G.T., et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J. Clin. Oncol. 2005, 23:1420-1430.
261. Farace F., Massard C., Vimond N., et al. A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas. Br. J. Cancer 2011, 105:847-853.
262. Meng S., Tripathy D., Shete S., et al. HER-2 gene amplification can be acquired as breast cancer progresses. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:9393-9398.
263. Bozionellou V., Mavroudis D., Perraki M., et al. Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer. Clin. Cancer Res. 2004, 10:8185-8194.
264. Xenidis N., Vlachonikolis I., Mavroudis D., et al. Peripheral blood circulating cytokeratin-19 mRNA-positive cells after the completion of adjuvant chemotherapy in patients with operable breast cancer. Ann. Oncol. 2003, 14:849-855.
265. Budd G.T., Cristofanilli M., Ellis M.J., et al. Circulating tumor cells versus imaging-predicting overall survival in metastatic breast cancer. Clin. Cancer Res. 2006, 12:6403-6409.
266. Xenidis N., Ignatiadis M., Apostolaki S., et al. Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. J. Clin. Oncol. 2009, 27:2177-2184.
267. Cristofanilli M., Broglio K.R., Guarneri V., et al. Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden. Clin. Breast Cancer 2007, 7:471-479.
268. Hayes D.F., Cristofanilli M., Budd G.T., Ellis M.J., et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin. Cancer Res. 2006, 12:4218-4224.
269. Yagata H., Nakamura S., Toi M., Bando H., Ohno S., Kataoka A. Evaluation of circulating tumor cells in patients with breast cancer: multi-institutional clinical trial in Japan. Int. J. Clin. Oncol. 2008, 13:252-256.
270. Nakamura S., Yagata H., Ohno S., et al. Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer. Breast Cancer 2010, 17:199-204.
271. Liu M.C., Shields P.G., Warren R.D., et al. Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. J. Clin. Oncol. 2009, 27:5153-5159.
272. De Giorgi U., Valero V., Rohren E., et al. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. J. Clin. Oncol. 2009, 27:3303-3311.
273. De Giorgi U., Valero V., Rohren E., et al. Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer. Ann. Oncol. 2010, 21:33-39.
274. Rack B.K., Schindlbeck C., Andergassen U., et al. Use of circulating tumor cells (CTC) in peripheral blood of breast cancer patients before and after adjuvant chemotherapy to predict risk for relapse: the SUCCESS trial. J. Clin. Oncol. 2010, 28:1003.
275. Hayashi N., Yamauchi H. Role of circulating tumor cells and disseminated tumor cells in primary breast cancer. Breast Cancer 2012, 19:110-117.